Alnylam's Stock Slumps 0.6% on Q4 Revenue Miss Despite 81% Full-Year Growth and 23% Volume Decline

Market Snapshot

Alnylam Pharmaceuticals (ALNY) closed on March 11, 2026, at $320.43, marking a 0.60% decline from the previous day’s close of $322.38. The stock traded within a range of $317.75 to $323.71, with a volume of 887,430 shares, representing a 23.06% drop compared to the prior day’s trading activity. Despite the decline, the company maintained a market capitalization of $42.496 billion, reflecting its position as a mid-cap biopharmaceutical player. The stock’s beta of 0.38 indicates relatively low volatility compared to the broader market, while its trailing twelve-month P/E ratio of 138.71 highlights its premium valuation relative to earnings.

Key Drivers

The recent price movement of Alnylam Pharmaceuticals appears tied to mixed quarterly performance and forward-looking guidance. On February 12, 2026, the company reported Q4 2025 earnings of $1.25 per share, slightly exceeding the $1.19 forecast. However, revenue of $1.1 billion fell short of the $1.15 billion estimate, contributing to a pre-market price drop of 2.08% to $315.58. This revenue shortfall, coupled with a 4.35% miss relative to expectations, likely pressured investor sentiment, as evidenced by the 0.60% intraday decline.

Full-year 2025 results, however, demonstrated resilience, with global net product revenues surging 81% to nearly $3 billion. Collaboration and royalty revenues grew by 8% and 90%, respectively, underscoring the company’s expanding partnerships and intellectual property monetization. Despite these gains, Q4 operating expenses of $93.331 million—a 20% year-over-year reduction—suggest ongoing cost management efforts. The company ended 2025 with $2.9 billion in cash and equivalents, alongside $850 million in non-GAAP operating income, reinforcing its financial stability.

Looking ahead, Alnylam’s 2026 guidance projects net product revenue between $4.9–$5.3 billion, implying a 71% growth at the midpoint. This aligns with its long-term target of 25% annual revenue growth through 2030. CEO Yvonne Greenstreet emphasized the company’s leadership in RNAi therapeutics, with plans to expand delivery mechanisms to 10 tissue types and advance over 40 clinical programs by 2030. These strategic initiatives, combined with a robust cash position, position Alnylam to capitalize on its pipeline and market share.

However, near-term challenges persist. The company’s debt-to-equity ratio of 1.28 and a current ratio of 2.76 indicate manageable leverage but highlight the need for disciplined capital allocation. Analysts forecast a 2026 EPS of -1.7, signaling potential profitability pressures despite revenue growth. Additionally, the recent underperformance in Q4 revenue, coupled with a 138.71 P/E ratio, suggests investors remain cautious about translating top-line growth into sustainable earnings.

The stock’s after-hours performance, with a 0.01% rise to $320.44, indicates limited near-term conviction in its near-term trajectory. While the 1-year target estimate of $457.00 implies long-term optimism, the gap between current prices and analyst targets underscores the need for stronger earnings momentum. Legal & General’s $404.83 million stake in Alnylam further signals institutional confidence, though it remains to be seen whether this will translate into broader market adoption.

In summary, Alnylam’s stock reflects a balance of optimism for its growth potential and caution over near-term execution risks. The company’s ability to meet 2026 revenue targets, manage operating expenses, and advance its RNAi pipeline will be critical in determining its path forward.